4-Hydroxyretinoic acid (4-HRA)是一种天然存在的,由全反式视黄酸(ATRA)经细胞色素P450酶代谢生成的主要代谢产物。
Cas No.:66592-72-1
Sample solution is provided at 25 µL, 10mM.
4-Hydroxyretinoic acid (4-HRA) is a naturally occurring, primary metabolite derived from all-trans retinoic acid (ATRA) via cytochrome P450 enzyme metabolism[1]. 4-Hydroxyretinoic acid can bind to retinoic acid receptors (RARs) to regulate gene expression, cell differentiation, and apoptosis, and also serves as a substrate for hepatic microsomal enzymes such as UGT2B7, thereby participating in immune regulation and neuroprotection[2,3]. 4-Hydroxyretinoic acid is commonly used as a marker of ATRA metabolism to study its conversion activity and regulatory mechanisms, and is also employed in research on acute promyelocytic leukemia and in the treatment of skin conditions such as psoriasis and acne[4,5,6].
References:
[1] SHIMSHONI J A, ROBERTS A G, SCIAN M, et al. Stereoselective formation and metabolism of 4-hydroxy-retinoic Acid enantiomers by cytochrome p450 enzymes[J]. Journal of Biological Chemistry, 2012, 287(50): 42223-42232.
[2] SAMOKYSZYN V M, GALL W E, ZAWADA G, et al. 4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase (s) and recombinant UGT2B7[J]. Journal of Biological Chemistry, 2000, 275(10): 6908-6914.
[3] DAS B C, THAPA P, KARKI R, et al. Retinoic acid signaling pathways in development and diseases[J]. Bioorganic & Medicinal Chemistry, 2014, 22(2): 673-683.
[4] WANG F, KWAK H S R, ELBULUK N, et al. Retinoic acid 4-hydroxylase inducibility and clinical response to isotretinoin in patients with acne[J]. Journal of the American Academy of Dermatology, 2009, 61(2): 252-258.
[5] ZOUBOULIS C C, VOORHEES J J, ORFANOS C E, et al. Topical all-trans retinoic acid (RA) induces an early, coordinated increase in RA-inducible skin-specific gene/psoriasin and cellular RA-binding protein II mRNA levels which precedes skin erythema[J]. Archives of Dermatological Research, 1996, 288(11): 664-669.
[6] IDRES N, BENOÎT G, FLEXOR M A, et al. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites[J]. Cancer Research, 2001, 61(2): 700-705.
4-Hydroxyretinoic acid (4-HRA)是一种天然存在的,由全反式视黄酸(ATRA)经细胞色素P450酶代谢生成的主要代谢产物[1]。4-Hydroxyretinoic acid可结合视黄酸受体(RARs),调控基因表达、细胞分化和凋亡,也是肝脏微粒酶(UGT2B7)的底物,参与免疫调控和神经保护[2,3]。4-Hydroxyretinoic acid通常作为ATRA代谢的标志物用于研究其转化活性与调控机制,也用于急性原骨髓细胞白血病的研究及皮肤疾病(如银屑病、痤疮)的治疗[4,5,6]。
| Cas No. | 66592-72-1 | SDF | |
| 别名 | 维甲酸杂质 | ||
| 化学名 | 4-hydroxy-retinoic acid | ||
| Canonical SMILES | CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(O)=O)C(C)(C)CCC1O | ||
| 分子式 | C20H28O3 | 分子量 | 316.4 |
| 溶解度 | DMSO : 100 mg/mL (316.03 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1606 mL | 15.8028 mL | 31.6056 mL |
| 5 mM | 632.1 μL | 3.1606 mL | 6.3211 mL |
| 10 mM | 316.1 μL | 1.5803 mL | 3.1606 mL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















